Effectiveness and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease and concomitant diabetes mellitus: a subgroup analysis of a randomized clinical trial
Abstract. Background:. Preliminary studies have indicated that Shexiang Baoxin Pill (MUSKARDIA) has a coronary artery dilation effect and increases the coronary blood flow, relieving the symptoms of angina. This study aimed to evaluate the benefit of MUSKARDIA on patients with stable coronary artery...
Main Authors: | Jingmin Zhou, Haiming Shi, Fusui Ji, Yang Wu, Yulan Zhao, Jun Qian, Junbo Ge, Yanjie Yin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2023-01-01
|
Series: | Chinese Medical Journal |
Online Access: | http://journals.lww.com/10.1097/CM9.0000000000002527 |
Similar Items
-
Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial
by: Haiming Shi, et al.
Published: (2022-10-01) -
Cost-effectiveness analysis of Shexiang Baoxin Pill (MUSKARDIA) as the add-on treatment to standard therapy for stable coronary artery disease in China.
by: Jie Pan, et al.
Published: (2024-01-01) -
Meta-analysis and trial sequential analysis of shexiang baoxin pill for coronary slow flow
by: Hongxin Guo, et al.
Published: (2022-08-01) -
Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: A systematic review and meta-analysis of 42 randomized controlled trials
by: Jingjing Wei, et al.
Published: (2022-11-01) -
Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria
by: Dan Wei, et al.
Published: (2018-03-01)